Preclinical testing of oncolytic adenovirus sensitivity in patient-derived tumor organoids

Patient-derived organoids (PDOs) have shown the potential to reflect patient sensitivity to chemotherapeutic or targeted drugs. Recently, we showed that or-ganoid models can also serve as a platform to screen for selectivity and potency of oncolytic adenoviruses (OAds). In this protocol, we describe the steps for tu-mor organoid adenoviral infection and functional assessment of patient-specific responses to OAds. We provide methods to determine OAd relative efficacy by evaluation of PDO viability after infection and adenoviral replication within can-cer cells. For complete details on the use and execution of this protocol, please refer to Raimondi et al. (2020).